Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LDL R


Brief Information

Name:LDL receptor
Target Synonym:FHCL1,Low-density lipoprotein receptor,LDLR,LDL receptor,Low Density Lipoprotein Receptor,Low-Density Lipoprotein Receptor Class A Domain-Containing Protein 3,Familial Hypercholesterolemia,LDLCQ2,FHC,FH,Receptors, LDL
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Loaded Rabbit LDL R, Fc Tag (Cat. No. LDR-R5255) on Protein A Biosensor, can bind Human Apolipoprotein E, His Tag (Cat. No. APE-H5246) with an affinity constant of 56.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Rabbit LDL R, Fc Tag (Cat. No. LDR-R5255) on Protein A Biosensor, can bind Human Apolipoprotein E, His Tag (Cat. No. APE-5256) with an affinity constant of 38.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Low-Density Lipoprotein (LDL) Receptor is also known  as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Phosphorylcholine monoclonal antibody PC-mAb Phase 2 Clinical Dyax Pharma ST Elevation Myocardial Infarction; Cardiovascular Diseases; Arteritis Details
Serpin Peptide 16 SP-16 Phase 2 Clinical Serpin Pharma Myocardial Infarction; Pneumonia; Coronavirus Disease 2019 (COVID-19); Inflammation Details
LLG-783 (Novartis) LLG-783 Phase 2 Clinical Novartis Pharma Ag Details
NGGT-006 NGGT-006; NGGT006 Phase 1 Clinical First Affiliated Hospital Of Xi’An Jiaotong University Homozygous familial hypercholesterolemia Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message